From genes to treatments: A systematic review of the pharmacogenetics in smoking cessation

Naji C. Salloum; Erica Lf Buchalter; Swati Chanani; Gemma Espejo; Mahjabeen S. Ismail; Randy O. Laine; Maysaa Nageeb; A. Benjamin Srivastava; Nicholas Trapp; Ludwig Trillo; Erica Vance; Michael Wenzinger; Sarah M. Hartz; Sean P. David; Li Shiun Chen

doi:10.2217/pgs-2018-0023

From genes to treatments: A systematic review of the pharmacogenetics in smoking cessation

Naji C. Salloum, Erica Lf Buchalter, Swati Chanani, Gemma Espejo, Mahjabeen S. Ismail, Randy O. Laine, Maysaa Nageeb, A. Benjamin Srivastava, Nicholas Trapp, Ludwig Trillo, Erica Vance, Michael Wenzinger, Sarah M. Hartz, Sean P. David, Li Shiun Chen

Research output: Contribution to journal › Review article › peer-review

13 Scopus citations

Abstract

Smoking cessation treatment outcomes may be heavily influenced by genetic variations among smokers. Therefore, identifying specific variants that affect response to different pharmacotherapies is of major interest to the field. In the current study, we systematically review all studies published in or after the year 1990 which examined one or more gene-drug interactions for smoking cessation treatment. Out of 644 citations, 46 articles met the inclusion criteria for the systematic review. We summarize evidence on several genetic polymorphisms (CHRNA5-A3-B4, CYP2A6, DBH, CHRNA4, COMT, DRD2, DRD4 and CYP2B6) and their potential moderating pharamacotherarpy effects on patient cessation efficacy rates. These findings are promising and call for further research to demonstrate the effectiveness of genetic testing in personalizing treatment decision-making and improving outcome.

Original language	English (US)
Pages (from-to)	861-871
Number of pages	11
Journal	Pharmacogenomics
Volume	19
Issue number	10
DOIs	https://doi.org/10.2217/pgs-2018-0023
State	Published - 2018
Externally published	Yes

Keywords

nicotine replacement therapy
pharmacogenetics
precision medicine
smoking cessation

ASJC Scopus subject areas

Molecular Medicine
Genetics
Pharmacology

Access to Document

10.2217/pgs-2018-0023

Cite this

Salloum, N. C., Buchalter, E. L., Chanani, S., Espejo, G., Ismail, M. S., Laine, R. O., Nageeb, M., Srivastava, A. B., Trapp, N., Trillo, L., Vance, E., Wenzinger, M., Hartz, S. M., David, S. P., & Chen, L. S. (2018). From genes to treatments: A systematic review of the pharmacogenetics in smoking cessation. Pharmacogenomics, 19(10), 861-871. https://doi.org/10.2217/pgs-2018-0023

@article{0539c44473064bc7ad8b874dc0105ecd,

title = "From genes to treatments: A systematic review of the pharmacogenetics in smoking cessation",

abstract = "Smoking cessation treatment outcomes may be heavily influenced by genetic variations among smokers. Therefore, identifying specific variants that affect response to different pharmacotherapies is of major interest to the field. In the current study, we systematically review all studies published in or after the year 1990 which examined one or more gene-drug interactions for smoking cessation treatment. Out of 644 citations, 46 articles met the inclusion criteria for the systematic review. We summarize evidence on several genetic polymorphisms (CHRNA5-A3-B4, CYP2A6, DBH, CHRNA4, COMT, DRD2, DRD4 and CYP2B6) and their potential moderating pharamacotherarpy effects on patient cessation efficacy rates. These findings are promising and call for further research to demonstrate the effectiveness of genetic testing in personalizing treatment decision-making and improving outcome.",

keywords = "nicotine replacement therapy, pharmacogenetics, precision medicine, smoking cessation",

author = "Salloum, {Naji C.} and Buchalter, {Erica Lf} and Swati Chanani and Gemma Espejo and Ismail, {Mahjabeen S.} and Laine, {Randy O.} and Maysaa Nageeb and Srivastava, {A. Benjamin} and Nicholas Trapp and Ludwig Trillo and Erica Vance and Michael Wenzinger and Hartz, {Sarah M.} and David, {Sean P.} and Chen, {Li Shiun}",

note = "Publisher Copyright: {\textcopyright} 2018 Future Medicine Ltd.",

year = "2018",

doi = "10.2217/pgs-2018-0023",

language = "English (US)",

volume = "19",

pages = "861--871",

journal = "Pharmacogenomics",

issn = "1462-2416",

publisher = "Future Medicine Ltd.",

number = "10",

}

TY - JOUR

T1 - From genes to treatments

T2 - A systematic review of the pharmacogenetics in smoking cessation

AU - Salloum, Naji C.

AU - Buchalter, Erica Lf

AU - Chanani, Swati

AU - Espejo, Gemma

AU - Ismail, Mahjabeen S.

AU - Laine, Randy O.

AU - Nageeb, Maysaa

AU - Srivastava, A. Benjamin

AU - Trapp, Nicholas

AU - Trillo, Ludwig

AU - Vance, Erica

AU - Wenzinger, Michael

AU - Hartz, Sarah M.

AU - David, Sean P.

AU - Chen, Li Shiun

PY - 2018

Y1 - 2018

N2 - Smoking cessation treatment outcomes may be heavily influenced by genetic variations among smokers. Therefore, identifying specific variants that affect response to different pharmacotherapies is of major interest to the field. In the current study, we systematically review all studies published in or after the year 1990 which examined one or more gene-drug interactions for smoking cessation treatment. Out of 644 citations, 46 articles met the inclusion criteria for the systematic review. We summarize evidence on several genetic polymorphisms (CHRNA5-A3-B4, CYP2A6, DBH, CHRNA4, COMT, DRD2, DRD4 and CYP2B6) and their potential moderating pharamacotherarpy effects on patient cessation efficacy rates. These findings are promising and call for further research to demonstrate the effectiveness of genetic testing in personalizing treatment decision-making and improving outcome.

AB - Smoking cessation treatment outcomes may be heavily influenced by genetic variations among smokers. Therefore, identifying specific variants that affect response to different pharmacotherapies is of major interest to the field. In the current study, we systematically review all studies published in or after the year 1990 which examined one or more gene-drug interactions for smoking cessation treatment. Out of 644 citations, 46 articles met the inclusion criteria for the systematic review. We summarize evidence on several genetic polymorphisms (CHRNA5-A3-B4, CYP2A6, DBH, CHRNA4, COMT, DRD2, DRD4 and CYP2B6) and their potential moderating pharamacotherarpy effects on patient cessation efficacy rates. These findings are promising and call for further research to demonstrate the effectiveness of genetic testing in personalizing treatment decision-making and improving outcome.

KW - nicotine replacement therapy

KW - pharmacogenetics

KW - precision medicine

KW - smoking cessation

UR - http://www.scopus.com/inward/record.url?scp=85049774010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049774010&partnerID=8YFLogxK

U2 - 10.2217/pgs-2018-0023

DO - 10.2217/pgs-2018-0023

M3 - Review article

C2 - 29914292

AN - SCOPUS:85049774010

SN - 1462-2416

VL - 19

SP - 861

EP - 871

JO - Pharmacogenomics

JF - Pharmacogenomics

IS - 10

ER -

From genes to treatments: A systematic review of the pharmacogenetics in smoking cessation

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this